Evidence map›Paper›PMID 26092101›Full record

ArticleCardiovascular research2015

Cross-talk between LOX-1 and PCSK9 in vascular tissues.

Zufeng Ding, Shijie Liu, Xianwei Wang, Xiaoyan Deng, Yubo Fan, Jiwani Shahanawaz, Robert J Shmookler Reis, Kattayi I Varughese, Tatsuya Sawamura, Jawahar L Mehta

Registry-linked trialOpen access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06675994 (Evaluation of PCSK9 Enzyme in Non-Cholesterol Biological Pathways), which is not on this map. Cited by 128 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed, 4 pooled it
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06675994 not yet recruitingstarted 2024, after this paper: background citation

Evaluation of PCSK9 Enzyme in Non-Cholesterol Biological Pathways: In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme

Ran2024Enrolled80Registered outcomes4Posted comparisons0ConditionsDiabetes, Family History of Cerebrovascular Disease, Family History of Coronary Artery Disease, Family History of Peripheral Artery DiseaseArmsPCSK9 Antibody, PCSK9 Enzyme
Open the trial in the graph
3 · Its place in the literature

Who cites it

128 citing papers in PubMed, 4 syntheses or guidelines pooled it, 229 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Evolocumab for prevention of microvascular dysfunction in patients undergoing percutaneous coronary intervention: the randomised, open-label EVOCATION trial.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2022
    Trial
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

68 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Zufeng DingCentral Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA Key Laboratory for Biomechanics and Mechanobiology of Ministry of Education, School of Biological Science and Medical Engineering, Beihang University, Beijing 100191, China.
Shijie LiuCentral Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA Key Laboratory for Biomechanics and Mechanobiology of Ministry of Education, School of Biological Science and Medical Engineering, Beihang University, Beijing 100191, China sliu2@uams.edu mehtajl@uams.edu.
Xianwei WangCentral Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Xiaoyan DengKey Laboratory for Biomechanics and Mechanobiology of Ministry of Education, School of Biological Science and Medical Engineering, Beihang University, Beijing 100191, China.
Yubo FanKey Laboratory for Biomechanics and Mechanobiology of Ministry of Education, School of Biological Science and Medical Engineering, Beihang University, Beijing 100191, China.
Jiwani ShahanawazCentral Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Robert J Shmookler ReisCentral Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Kattayi I VarugheseCentral Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Tatsuya SawamuraDepartment of Physiology, Shinshu University School of Medicine, 3-1-1, Asahi, Matsumoto 390-8621, Japan.
Jawahar L MehtaCentral Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA sliu2@uams.edu mehtajl@uams.edu.
University of Arkansas for Medical Sciences · USBeihang University · CNCentral Arkansas Veterans Healthcare System · USShinshu University · JP

Funding

PCSK9-A novel target for the treatment of myocardial ischemiaI01BX000282 · VA · CENTRAL ARKANSAS VETERANS HLTHCARE SYS · PI MEHTA, JAWAHAR L · 2009 to 2022
–
BLRD VA I01 BX000282
6 · The paper itself

Abstract

aimsLectin-like ox-LDL receptor-1 (LOX-1) plays an important role in inflammatory diseases, such as atherosclerosis. Proprotein convertase subtilisin/kexin type 9 (PCSK9) modulates LDL receptor degradation and influences serum LDL levels. The present study was designed to investigate the possible interaction between PCSK9 and LOX-1. METHODS AND

resultsIn the first set of experiments, human vascular endothelial cells and smooth muscle cells were studied at baseline and after lipopolysaccharide (LPS) treatment (to create an inflammatory state). Both PCSK9 and LOX-1 were strongly induced by LPS treatment. To define the role of PCSK9 in LOX-1 expression, cells were transfected with siRNA against PCSK9, which resulted in reduced LOX-1 expression and function. On the other hand, cells exposed to recombinant hPCSK9 revealed enhanced LOX-1 expression (P < 0.05). To determine whether LOX-1 also regulates PCSK9, cultured cells in which LOX-1 was knocked down by siRNA expressed less PCSK9, whereas those transfected with hLOX-1 cDNA showed increased PCSK9 expression. The second set of experiments was carried out in wild-type (WT) and gene knockout (KO; LOX-1 and PCSK9) mice; LOX-1 KO mice showed much less PCSK9 (P < 0.05 vs. WT mice). PCSK9-KO mice showed much less LOX-1 (P < 0.05 vs. WT mice). Furthermore, we observed that mitochondrial reactive oxygen species (mtROS) plays an initiating role in the LOX-1/PCSK9 interaction, since mtROS induction enhanced and its inhibition reduced the expression of both PCSK9 and LOX-1. We also found that both LOX-1 and PCSK9 regulate adhesion molecules vascular cell adhesion molecule-1 expression. Finally, oxidized low-density lipoprotein and tumour necrosis factor-α, pro-inflammatory stimuli besides LPS, regulated PCSK9 expression that is mediated by the NF-κB signalling pathway.

conclusionsThese observations suggest that LOX-1 and PCSK9 positively influence each other's expression, especially during an inflammatory reaction. mtROS appear to be important initiators of PCSK9/LOX-1 expression.

Indexed as

AnimalsCells, CulturedEndothelial CellsLipopolysaccharidesLipoproteins, LDLMiceMice, KnockoutMyocytes, Smooth MuscleNF-kappa BProprotein Convertase 9Proprotein ConvertasesReactive Oxygen SpeciesScavenger Receptors, Class ESerine EndopeptidasesVascular Cell Adhesion Molecule-1LipopolysaccharidesLipoproteins, LDLNF-kappa BOlr1 protein, mouseoxidized low density lipoproteinPcsk9 protein, mouseProprotein Convertase 9Proprotein ConvertasesReactive Oxygen SpeciesScavenger Receptors, Class ESerine EndopeptidasesVascular Cell Adhesion Molecule-1LOX-1Mitochondrial ROSPCSK9VCAM-1

Identifiers

PMID26092101
OpenAlexW2194274372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.